The low price for Epizyme is due to their drug bei
Post# of 148183
(Total Views: 516)
Posted On: 06/27/2022 3:35:29 PM
The low price for Epizyme is due to their drug being approved only for relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation. A very narrow market. They do have a SETD2 inhibitor but it's in development. Their drugs are nothing like the widespread potential of leronlimab.
(12)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼